Free Trial
OTCMKTS:MDGEF

Medigene (MDGEF) Stock Price, News & Analysis

$1.30 0.00 (0.00%)
(As of 12/20/2024 ET)

About Medigene Stock (OTCMKTS:MDGEF)

Key Stats

Today's Range
$1.30
$1.30
50-Day Range
$1.30
$1.30
52-Week Range
$1.10
$1.30
Volume
N/A
Average Volume
600 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDGEF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDGEF Stock News Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Q2 2024 Medigene AG Earnings Call Transcript
See More Headlines

MDGEF Stock Analysis - Frequently Asked Questions

Medigene's stock was trading at $3.00 at the beginning of the year. Since then, MDGEF shares have decreased by 56.8% and is now trading at $1.2950.
View the best growth stocks for 2024 here
.

Medigene's stock reverse split on the morning of Saturday, January 1st 2000. The 1-2 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:MDGEF
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (OTCMKTS:MDGEF) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners